Skip to content
The Nexus
DossierENTITY

50 to 64

Coverage of 50 to 64 in the Nexus archive.

Earliest in view: Jun 18 · 22:31 UTCMost recent: Jun 18 · 22:31 UTC
Co-mentioned in this coverage
FDAorganization1Modernaorganization1mFlusivatopic1mRNA flu vaccinetopic1FDA advisory panelorganization165 and oldertopic1
Recent coverage
  • HEALTHJun 18 · 22:31 UTCTHE HILL
    FDA panel recommends mRNA flu vaccine for older adults

    An FDA advisory panel unanimously recommended Moderna’s mRNA-based flu vaccine, mFlusiva, for approval in adults aged 50-64 and 65+. The panel voted 9-0 that the benefits outweigh the risks for the vaccine.

50 to 64 · Dossier · The Nexus